Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2016 01:00 ET | Source: Relypsa, Inc.

FDA Approves Supplemental New Drug Application for Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions

The updated label recommends patients take Veltassa at least 3 hours before or after other oral medications; previously the label recommended a 6-hour separation timeData from the drug-drug...
November 03, 2016 16:30 ET | Source: Relypsa, Inc.

Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016

REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Company, today announced five posters, including new analyses from studies of Veltassa® (patiromer) for oral...
August 30, 2016 16:05 ET | Source: Relypsa, Inc.

Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia

REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and...
July 21, 2016 01:00 ET | Source: Relypsa, Inc.; Galenica Group

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa

– Acquisition Strengthens Galenica’s Business Unit, Vifor Pharma – Galenica will commence a tender offer to acquire all issued and outstanding Relypsa common stock for a cash consideration of...
July 18, 2016 16:15 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company’s...
July 06, 2016 08:30 ET | Source: Relypsa, Inc.

Relypsa to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

REDWOOD CITY, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald...
June 27, 2016 16:16 ET | Source: Relypsa, Inc.

Results of Pre-Specified Exploratory Analysis of Phase 3 OPAL-HK Study Evaluating Effects of Veltassa on Blood Pressure and Aldosterone Published in Kidney International

REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3...
June 17, 2016 16:10 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 15, 2016, the compensation committee of the company’s...
June 06, 2016 16:15 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company’s...
May 25, 2016 16:15 ET | Source: Relypsa, Inc.

Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies

REDWOOD CITY, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right